Sanofi is a leading Paris-based healthcare company. Formerly known as Sanofi-Aventis, the company changed its name to Sanofi in May 2011. It operates in three main areas: pharmaceuticals, vaccines and consumer healthcare. Sanofi developed a COVID-19 vaccine in collaboration with GlaxoSmithKline.[1] As of year-end 2020, the company employed more than 100,000 people in 90 countries and did business in 170 countries.[2]
Sanofi, whose ticker symbol is SAN, earned a net income of €12.3 billion for full-year 2020, which was up 339%. This was largely due to a capital gain from the sale of shares in Regeneron, a U.S. based pharmaceutical company. Sales rose 3.3% to €36.0 billion.[3]
In May 2020 Sanofi announced the public sale of 13 million shares of Regeneron at US$515.00 per share. In addition, it sold nearly 10 million shares of stock directly to Regeneron, for total proceeds of US$11.7 billion. Sanofi continues to retain 400,000 Regeneron shares.[4]
| Retrieved 19 May 2021 https://finance.yahoo.com/quote/SNY/profile | |
| Retrieved 19 May 2021 https://www.sanofi.com/en/about-us | |
| Retrieved 19 May 2021 https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/2021_02_05_Results_PR_EN.pdf | |
| Retrieved 19 May 2021 https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-29-22-01-00 |
| Retrieved 19 May 2021 https://finance.yahoo.com/quote/SNY/profile | |
| Retrieved 19 May 2021 https://www.sanofi.com/en/about-us | |
| Retrieved 19 May 2021 https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/2021_02_05_Results_PR_EN.pdf | |
| Retrieved 19 May 2021 https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-29-22-01-00 |
When executing customers' trades, FXCM can be compensated in several ways, which include, but are not limited to: spreads, charging commissions at the open and close of a trade, and adding a mark-up to rollover, etc. Commission-based pricing is applicable to Active Trader account types.
Third Party Links: Links to third-party sites are provided for your convenience and for informational purposes only. FXCM bears no liability for the accuracy, content, or any other matter related to the external site or for that of subsequent links, and accepts no liability whatsoever for any loss or damage arising from the use of this or any other content. Such sites are not within our control and may not follow the same privacy, security, or accessibility standards as ours. Please read the linked websites' terms and conditions.
Any opinions, news, research, analyses, prices, other information, or links to third-party sites contained on this website are provided on an "as-is" basis, as general market commentary and do not constitute investment advice. The market commentary has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is therefore not subject to any prohibition on dealing ahead of dissemination. Although this commentary is not produced by an independent source, FXCM takes all sufficient steps to eliminate or prevent any conflicts of interests arising out of the production and dissemination of this communication. The employees of FXCM commit to acting in the clients' best interests and represent their views without misleading, deceiving, or otherwise impairing the clients' ability to make informed investment decisions. For more information about the FXCM's internal organizational and administrative arrangements for the prevention of conflicts, please refer to the Firms' Managing Conflicts Policy. Please ensure that you read and understand our Full Disclaimer and Liability provision concerning the foregoing Information, which can be accessed here.